Novo Nordisk Licenses Chinese Oral Obesity Candidate as Heart-Data Edge and FDA Setback Define a Busy Fortnight

Novo Nordisk licensed an oral GLP-1/GIP drug from Hengrui for up to $2.6 billion, as Ozempic data showed a cardiovascular edge over tirzepatide.

Novo Nordisk has moved to deepen its metabolic pipeline on two fronts at once, signing a global licensing deal for an experimental oral drug while rolling out clinical evidence that its flagship semaglutide franchise holds a cardiovascular edge over rival tirzepatide. The twin developments landed alongside a regulatory delay in the company's hemophilia portfolio and a share price still nursing a 25% year-to-date decline.

A $2.6 Billion Wager on a Pill

Under an exclusive worldwide license unveiled Tuesday, the Danish drugmaker secured rights to HRS-1596, an oral dual GLP-1/GIP receptor agonist from China's Hengrui Pharma that is ready to enter Phase 1 testing. The agreement carries a potential total value of up to $2.6 billion, anchored by a $300 million upfront payment. Hengrui would also collect success-based milestone payments and potential revenue participation.

The licensed territory spans the globe but carves out mainland China, Hong Kong, Macau and Taiwan. Closing is subject to customary conditions and is expected in the fourth quarter of 2026. For Novo Nordisk, the pact buys early access to a novel oral approach that engages two of the body's own signaling pathways — a strategic hedge as it works to push beyond injectable formats.

Scaling Up Oral Capacity

The Hengrui deal slots into a roadmap management laid out roughly two weeks ago, when it pledged to dramatically expand manufacturing capacity for oral GLP-1 therapies. By 2030, the company aims to treat ten times as many people with obesity using tablet forms. It also wants to bring more than five so-called multi-blockbuster medicines to market and reach over 60 million patients worldwide by the same deadline — targets the company explicitly framed as strategic ambitions rather than financial guidance.

Fresh real-world data reinforced the appetite for pills. In the OCTANE study, adults who switched from injectable GLP-1 therapies to the Wegovy tablet and stayed on treatment for three months shed an average of 4.1% of their body weight. Presented Wednesday at the annual meeting of the European Association for the Study of Diabetes, the findings reflect routine clinical practice rather than the tightly controlled conditions of a registration trial.

Ozempic's Cardiovascular Edge

A day earlier, Novo Nordisk had unveiled a large registry analysis drawing on 636,525 adults with type 2 diabetes. Patients on the 2-milligram dose of Ozempic showed a statistically significant 6% lower risk of major cardiovascular events than those switched to tirzepatide. That result sharpens Ozempic's competitive profile in a market where the two manufacturers are battling for dominance, and where payers treat cardiovascular outcomes data as a decisive factor in reimbursement decisions.

Hemophilia Filing Slips on Plant Fixes

Not every thread moved in the company's favor. The U.S. Food and Drug Administration has extended its review of the application for Denecimig, a treatment for hemophilia A, citing ongoing remediation work at a production facility. The agency raised no concerns about the efficacy or safety data. Novo Nordisk said the delay will not affect its 2026 financial outlook and continues to target a U.S. launch in the first half of 2027.

Shares Stay Under Pressure

Investors have yet to be won over. Novo Nordisk stock closed Friday at EUR 33.06, leaving it down 25% since the start of the year. Skepticism over the long-term growth targets sketched out two weeks ago triggered a noticeable pullback, and CFRA analyst Wan Nurhayati cut her rating on the U.S. depositary receipts to "Sell" from "Hold" on September 22, setting a $38 price target. Even so, the latest licensing move signals that management is prepared to deploy available capital into the growth fields of the future.